乔钰惠,江 彤

随着生活水平的提高、人口老龄化的加剧，糖尿病已成为除肿瘤、冠心病、脑血管病之外的第4种威胁人类健康的疾病。近年来，胰高血糖素在2型糖尿病发生和发展中的关键作用日益得到重视。基于胰高血糖素研制的胰高血糖素样肽1受体激动剂已开始应用于临床。胰高血糖素样肽1受体激动剂除了降低血糖，还保护心血管系统、降低血压、调节血脂、减重等。但同时胰高血糖素样肽１受体激动剂也引起了恶心、恶心、呕吐等一系列胃肠道不良反应，本文就胰高血糖素样肽1受体激动剂在2型糖尿病患者中产生的胃肠道不良反应作一综述，为其治疗提供参考。

胰高血糖素；胰高血糖素样肽1受体激动剂；2型糖尿病；胃肠道不良反应

[1] AHMAD E,LIM S,LAMPTEY R,et al.Type 2 diabetes[J].Lancet,2022,400(10365):1803-1820. [2] CESURS,CAMME,SAYINFS,etal.Metformin-loadedpolymerbasedmicrobubbles/nanoparticlesgeneratedforthetreatmentoftype2diabetesmellitus[J]. Langmuir,2022,38(17):5040-5051. [3] 刁亚丽,徐明付.2型糖尿病患者慢性并发症临床特点及相关因素[J].当代医学,2018,24(2):16-18. [4] Inzucchi SE,Bergenstal RM,Buse JB,Diamant M,Ferrannini E,Nauck M,Peters AL,Tsapas A,Wender R,Matthews DR.Management of hyperglycemia in type 2 diabetes,2015:a patient-centered approach:update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes Care.2015 Jan;38(1):140-9. [5] Dailey G,Admane K,Mercier F,et al.Relationship of insulin dose,a1c lowering,and weight in type 2 diabetes:comparing insulin glargine and insulin detemir[J].Diabetes Technol Ther,2010,12(12):1019-1027. [6] Holst JJ,Gromada J.Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.Am J Physiol Endocrinol Metab.2004 Aug;287(2):E199-206. [7] MacDonald PE,El-Kholy W,Riedel MJ,Salapatek AM,Light PE,Wheeler MB.The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion.Diabetes.2002 Dec;51 Suppl 3:S434-42. [8]Nakagawa A,Satake H,Nakabayashi H,et al.Receptor gene expres-sion of glucagon-like peptide-1,but not glucose-dependent insulino-tropic polypeptide,in rat nodose ganglion cells[J].Auton Neurosci,2004,110(1):36-43. [9] Cantini,G.;Mannucci,E.;Luconi,M.Perspectives in GLP-1 research:new targets,new receptors.Trends Endocrinol.Metab.2016,27,427–438. [10] Doliba N M,Qin W,Vatamaniuk M Z,et al.Restitution of defective glucose-stimulated insulin release of sulfonylurea type 1 receptor knockout mice by acetylcholine[J].Am J Physiol Endocrinol Metab,2004,286(5),E834-E843. [11] Madsbad S.Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists[J].Diabetes Obes Metab,2016,18(4):317-332. [12] Singh S,Wright E E Jr,Kwan A Y,et al.Glucagon-like peptide-1 receptor agonists compared with basalinsulins for the treatment of type2 diabetes mellitus:a systematic review and meta-analysis[J].Diabetes Obes Metab,2017,19(2):228-238. [13] Htike Z Z,Zaccardi F,Papamargaritis D,et al.Efficacy andsafetyof glucagon-like peptide-1 receptor agonists in type2 diabetes:a systematic review and mixed-treatment comparisonanalysis[J].Diabetes Obes Metab,2017,19(4):524-536. [14] 高峰,李利萍,李欢,等.糖尿病的前沿治疗药物与治疗方案[J].医药导报,2016,35(7):679-687. [15] 郑少茹,张洁,王战建,等.胰高血糖素样肽-1改善胰岛功能的研究进展[J].疑难病杂志,2016,15(5):542-545. [16] NAUCK MA,QUAST DR,WEFERS J,et al.GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art[J].Mol Metab, 2021,46:101102. [17] NAUCK M A,QUAST D R,WEFERS J,et al.GLP-1 re ceptor agonists in the treatment of type 2 diabetes:state of-the-art[J].Mol Metab, 2021,46:101102. [18] GORGOJO-MARTÍNEZ J J,MEZQUITA-RAYA P,CARRETERO-GÓMEZ J,et al.Clinical recommenda tions to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists:a multidisciplinary expert consensus[J].J Clin Med,2022,12(1):145. [19] O’NEIL P M,BIRKENFELD A L,MCGOWAN B,et al.Efficacy and safety of semaglutide compared with liraglu tide and placebo for weight loss in patients with obesity:a randomised,double-blind,placebo and active controlled,dose-ranging,phase 2 trial[J].Lancet, 2018,392(10148):637-649. [20] SODHI M,REZAEIANZADEH R,KEZOUH A,et al.Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss[J].JAMA,2023,330(18):1795-1797. [21] HOLST J J.The physiology of glucagon-like peptide 1[J].Physiol Rev,2007,87(4):1409-1439. [22] JASTREBOFF A M,ARONNE L J,AHMAD N N,et al.Tirzepatide once weekly for the treatment of obesity[J].N Engl J Med, 2022,387(3):205-216. [23] ANDERSEN A,KNOP F K,VILSBØLL T.A pharmaco logical and clinical overview of oral semaglutide for the treatment of type 2 diabetes[J].Drugs,2021,81(9):1003-1030. [24] WHARTON S,CALANNA S,DAVIES M,et al.Gastroin testinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity,and the relationship be tween gastrointestinal adverse events and weight loss[J].Diabetes Obes Metab,2022,24(1):94-105. [25] Lyseng-Williamson KA.Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes:Their Use and Differential Features.Clin Drug Investig.2019 Aug;39(8):805-819. [26] Garber A,Henry R,Ratner R,García-Hernández PA,Rodrigeuz-Pattzi H,OlveraÁlvarez I,et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3 Mono):a randomised,52-week,phase III,double-blind,parallel treatment trial.Lancet.2009;373:473-81. [27] DeFronzo RA,Ratner RE,Han J,Kim DD,Fineman MS,Baron AD.Effects of exenatide(exendin-4)on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.Diabetes Care.2005;28:1092-100. [28] Nauck M,Frid A,Hermansen K,Shah NS,Tankova T,Mitha IH,et al.Efficacy and safety comparison of liraglutide,glimepiride,and placebo,all in combination with metformin,in type 2 diabetes:the LEAD(Liraglutide Effect and Action in Diabetes)-2 study.Diabetes Care.2009;32:84-90. [29] Bolli GB,Munteanu M,Dotsenko S,Niemoeller E,Boka G,Wu Y,et al.Efficacy and safety of lixisenatide once daily vs.placebo in people with Type 2 diabetes insufficiently controlled on metformin(GetGoal-F1).Diabet Med.2014;31:176-84. [30] Buse JB,Henry RR,Han J,Kim DD,Fineman MS,Baron AD,et al.Effects of exenatide(exendin-4)on glycemic control over 30 weeks in sulfonylurea treated patients with type 2 diabetes.Diabetes Care.2004;27:2628-35. [31] Marre M,Shaw J,Brändle M,Bebakar WM,Kamaruddin NA,Strand J,et al.Liraglutide,a once-daily human GLP-1 analogue,added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes(LEAD-1 SU).Diabet Med.2009;26:268-78. [32] Ratner R,Hanefeld M,Shamanna P,Min K,Boka G,Miossec P,et al.Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea+ metformin(GetGoal-S)[abstract 785].Diabetologia.2011;54:S317. [33] Kendall DM,Riddle MC,Rosenstock J,Zhueang D,Kim DD,Fineman MS,et al.Effects of exenatide(exendin-4)on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.Diabetes Care.2005;28:1083-91. [34] Diamant M,Van GL,Stranks S,Northrup J,Cao D,Taylor K,et al.Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes(DURATION-3):an open-label randomised,parallel-group,open-label trial.Lancet.2010;375:1447-56. [35] Drucker DJ,Buse JB,Taylor K,Kendall DM,Trautmann M,Zhuang D,et al.Exenatide once weekly versus twice daily for the treatment of type 2 diabetes:a randomised,open-label,non-inferiority study.Lancet.2008;372:1240-50. [36] Ørskov C,Poulsen SS,Møller M,Holst JJ.Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon like peptide I.Diabetes.1996;45:832-5. [37] Buse JB,Nauck M,Forst T,Sheu WH,Shendouda SK,Heilmann CR,et al.Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes(DURATION-6):a randomized,open-label study.Lancet.2013;381:117-24. [38] Rosenstock J,Raccah D,Korányi L,Maffei L,Boka G,Miossec P,et al.Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin:a 24-week,randomized,open-label,active-controlled study(GetGoal-X). Diabetes Care.2013;36:2945-51. [39] 郑彩云,林妹妹,戴亨纷.GLP-1受体激动剂致2型糖尿病患者胃肠道不良反应的网状Meta分析[J].中国新药与临床杂志, 2024,43(06):460-468. [40] Juhl CB,Hollingdal M,Sturis J,Jakobsen G,Agerso H,Veldhuis J,et al.Bedtime administration of NN2211,a long-acting GLP-1 derivative,substantially reduces fasting and postprandial glycemia in type 2 diabetes.Diabetes.2002;51:424-9 [41] Feinle C,Christen M,Grundy D,Faas H,Meier O,Otto B,et al.Effects of duodenal fat,protein or mixed-nutrient infusions on epigastric sensations during sustained gastric distension in healthy humans.Neurogastroenterol Motil.2002;14:205-13. [42] Thiele TE,Van Dijk G,Campfield LA,Smith FJ,Burn P,Woods SC,et al.Central infusion of GLP-1,but not leptin,produces conditioned taste aversions in rats.Am J Physiol.1997;272:R726-30. [43] Tang-Christensen M,Cowley MA.GLP-1 analogs:satiety without malaise?Am J Physiol Regul Integr Comp Physiol.2007;293:R981-2 [44] BARABOI ED,ST-PIERRE DH,SHOONER J,et al.Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4[J].Am J Physiol Regul Integr Comp Physiol,2011, 301(4):R1011-R1024. [45] Byetta®(exenatide injection):highlights of prescribing information.Disponibleen:ttp://www.accessdata.fda.gov/ drugsatfda_docs/ label /2010/021773s028lbl.

点击下载PDF